Septerna, Inc. (SEPN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−34.4x

Market Cap

$1.72B

MomentumView details →

1D Return

−0.14%

YTD Return

+31.91%

RSI (14)

41.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−34.4x

Market Cap

$1.72B

RSI (14)

41.1

MomentumView details →

1D Return

−0.14%

YTD Return

+31.91%

SummaryUpdated Jun 1, 2026

Septerna, Inc. (NASDAQ:SEPN) is a clinical-stage biotechnology company founded in 2019 and headquartered in South San Francisco, California. Originally incorporated as GPCR NewCo, Inc., the company changed its name to Septerna Inc. in June 2021 and went public in October 2024. Septerna focuses on discovering and developing oral small molecule drug candidates that target G protein-coupled receptors (GPCRs) for treating endocrinology, immunology, inflammation, and metabolic diseases.

Ask drillr about Septerna, Inc. →

ProfitabilityView details →

Gross Margin

99.57%

Net Margin

−24.51%

EBITDA Margin

−40.20%

ROE (TTM)

−6.27%

ROA (TTM)

−4.28%

Asset Turnover

0.17x

GrowthView details →

Revenue YoY

—

EPS YoY

+75.23%

FCF YoY

+226.57%

Revenue CAGR 3Y

+1644.45%

EPS CAGR 3Y

+43.01%

EBITDA YoY

+56.81%

EarningsView details →

EPS (Actual)

−$0.29

EPS Surprise

31.92%

Beats (12Q)

4/12

Next Q EPS Est

−$0.42

Avg Surprise (4Q)

17.84%

Rev Surprise

39.14%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

4.99x

Quick Ratio

4.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

98.88M

Net Income (TTM)

−24.24M

Op. CF (TTM)

106.01M

Next earningsNov 9, 2026 →

Latest newsMore news →

RA Capital Management, L.P., a significant shareholder and director of Septerna, Inc., sold 1,493,000 shares of Septerna common stock for $63,452,500 on August 12, 2026.21d ago

Septerna, Inc. reported a second-quarter net loss of $0.29 per share, beating the Zacks Consensus Estimate of a $0.48 loss and improving from a $0.56 loss a year earlier.25d ago

Similar companies

Tyra Biosciences, Inc.TYRA Novavax, Inc.NVAX Fortrea Holdings Inc.FTRE AnaptysBio, Inc.ANAB Eton Pharmaceuticals, Inc.ETON Inhibrx Biosciences, Inc.INBX Find similar companies →

Latest newsMore news →

RA Capital Management, L.P., a significant shareholder and director of Septerna, Inc., sold 1,493,000 shares of Septerna common stock for $63,452,500 on August 12, 2026.21d ago Septerna, Inc. reported a second-quarter net loss of $0.29 per share, beating the Zacks Consensus Estimate of a $0.48 loss and improving from a $0.56 loss a year earlier.25d ago